Early Phase 1 Peripheral Arterial Disease Trial, Recruiting NCT06319339 Sponsor: University of Nebraska Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Early Phase 1 Peripheral Arterial Disease Trial, Recruiting

NCT06319339
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with peripheral artery disease (PAD) — reduced blood flow to the legs:

  • People who are able to sign a written consent form agreeing to take part
  • People aged between 50 and 75 years
  • People diagnosed with PAD at a stage where walking causes leg pain (Fontaine stage II or III)
  • People who have a history of leg pain brought on by exercise or walking
  • Women who have gone through menopause, meaning periods stopped more than 24 months ago
  • People whose kidneys are working normally, or have shown stable kidney function in the last 6 months (confirm with trial site)
  • People whose liver is working normally, or have shown stable liver function in the last 6 months (confirm with trial site)
  • People whose blood test results fall within the normal ranges for red blood cells, haemoglobin, white blood cells, platelets, and lymphocytes — or have shown stable blood counts in the last 6 months (confirm with trial site)

For healthy comparison participants (age-matched controls):

  • People who are able to sign a written consent form agreeing to take part
  • People aged between 50 and 75 years
  • People with no sign of blocked or narrowed arteries in the legs, as measured by a standard blood pressure comparison test
  • Women who have gone through menopause, meaning periods stopped more than 24 months ago
  • People whose kidneys are working normally, or have shown stable kidney function in the last 6 months (confirm with trial site)
  • People whose liver is working normally, or have shown stable liver function in the last 6 months (confirm with trial site)
  • People whose blood test results fall within the normal ranges for red blood cells, haemoglobin, white blood cells, platelets, and lymphocytes (confirm with trial site)

Who may not be able to join:

For people with PAD:

  • People whose PAD causes pain while resting, or has led to tissue damage, wounds, ulcers, gangrene, or skin death in the foot (the most severe stage of PAD)
  • People who have had a sudden blockage or injury causing reduced blood flow to a leg
  • People whose walking is limited by conditions other than PAD
  • People who have not had a physical examination to assess their ability to exercise in the past year
  • People who are currently pregnant or breastfeeding
  • People whose kidney or liver function test results are outside the normal ranges
  • People diagnosed with multiple sclerosis or psoriasis
  • People diagnosed with certain gut conditions, such as moderate irritable bowel syndrome or Crohn's disease
  • People currently taking a medication called dimethyl fumarate
  • People who have had an allergic reaction to diroximel fumarate, dimethyl fumarate, or any ingredient in the medication VUMERITY
  • People whose blood test results fall outside the required normal ranges

For healthy comparison participants:

  • People who have been diagnosed with PAD
  • People who have not had a physical examination to assess their ability to exercise in the past year
  • People whose last physical examination identified any limitations to exercise
  • People whose walking ability is limited due to a muscle or joint injury
  • People who are currently pregnant or breastfeeding
  • People whose kidney function test results are outside the normal ranges
  • People whose liver function test results are outside the normal ranges
  • People whose blood test results fall outside the required normal ranges

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Gwenael Layec, PhD, University of Nebraska

Phone: 402-554-3224

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
University of Nebraska
Registry
ClinicalTrials.gov
Start date
14 November 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Macrovascular Endothelial Function; Oxygen Transfer and Utilization; Femoral and Popliteal Artery Blood Flow; Walking capacity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov